サンプル依頼リスト カート
  • English
  • Korean
表紙：不活化ワクチンの世界市場レポート 2024年
市場調査レポート
商品コード
1415765

不活化ワクチンの世界市場レポート 2024年

Inactivated Vaccines Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
不活化ワクチンの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

不活化ワクチンの市場規模は近年着実に成長しています。2023年の59億5,000万米ドルから2024年には61億9,000万米ドルへとCAGR4.2％で拡大します。実績期間の成長は、ポリオ撲滅活動、インフルエンザ予防接種プログラム、新興感染症、規制当局の承認に起因しています。

不活化ワクチンの市場規模は、今後数年間で安定した成長が見込まれます。2028年には年間平均成長率（CAGR）4.3％で73億3,000万米ドルに成長します。予測期間の成長は、パンデミックへの備え、ワクチン適用範囲の拡大、バイオ製造の進歩、健康公平性への取り組みに起因すると考えられます。予測期間における主な動向には、MRNAワクチンプラットフォーム、混合ワクチン、耐熱性ワクチン、デジタルワクチンパスポートなどがあります。

感染症の流行の高まりが、不活化ワクチン市場の今後の拡大を牽引すると予想されます。感染症は、細菌、ウイルス、真菌、寄生虫を含む様々な病原体によって引き起こされる病気で、個人間で感染し、様々な症状や健康合併症を引き起こします。特に結核は代表的な感染症です。不活化ワクチンは、免疫反応を引き起こすために非生物病原体を使用し、ポリオ、A型肝炎、インフルエンザなどの病気から効果的に守っています。その一例として、世界保健機関（WHO）が2022年10月に発表した「世界結核報告書」によると、2021年の世界の結核罹患者数は1,010万人から1,060万人へと4.5％増加すると予測されています。東南アジア地域が結核症例全体の45％を占め、アフリカは23％を報告しました。このように、感染症の流行拡大は不活化ワクチン市場拡大の主要因となっています。

予防接種イニシアチブの増加は、今後数年間の不活化ワクチン市場の成長を促進する構えです。予防接種の取り組みには、特定の感染症に対するワクチン接種を個人や地域社会に提供し、最終的にこれらの健康上の脅威から人々を守ることを目的とした組織的なキャンペーンや取り組みが含まれます。予防接種イニシアチブの拡大は、不活化ワクチン市場の重要なファクターを構成しています。予防接種キャンペーンの普及は、不活化ワクチンに対する需要の増加をもたらし、市場の成長を刺激し、研究開発への投資を促します。例えば、スイスに本部を置く政府間機関である世界保健機関（WHO）のデータによると、肝炎、ジフテリア、破傷風、百日咳、麻疹、ポリオなどの感染症により、世界で毎年400万～500万人の命が失われるのをワクチンが防いでいます。さらに、2022年には、世界の乳幼児の約84％がポリオワクチンを3回接種しています。同様に、経口ポリオワクチン（OPV）を使用している国では、推定84％の乳幼児が同年中に不活化ポリオワクチン（IPV）の初回接種を受けています。その結果、予防接種への取り組みの高まりが、不活化ワクチン市場拡大の原動力となっています。

2023年の不活化ワクチン市場で最大の地域は北米でした。アジア太平洋は予測期間中に最も急成長する地域と予想されます。不活化ワクチンレポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の不活化ワクチン市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • ウイルスワクチン
  • 細菌ワクチン
  • 世界の不活化ワクチン市場、不活化方法別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 溶剤系洗剤
  • 放射線
  • pH濃度
  • 熱不活化
  • 他の不活化方法
  • 世界の不活化ワクチン市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • その他の流通チャネル

第7章 地域および国の分析

  • 世界の不活化ワクチン市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の不活化ワクチン市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 不活化ワクチン市場の競合情勢
  • 不活化ワクチン市場企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Services Inc.
    • Sinopharm Group Co. Ltd.
    • Merck &Co. Inc.
    • Sanofi SA

第31章 その他の主要および革新的な企業

  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma Inc.
  • CSL Limited
  • Daiichi Sankyo Company Limited
  • Mitsubishi Tanabe Pharma Corporation
  • Novavax Inc.
  • Zydus Lifesciences Ltd.
  • Sinovac Biotech Ltd.
  • Biological E Limited
  • Hualan Biological Engineering Inc.
  • CanSino Biologics Inc.
  • Shenzhen Kangtai Biological Products Co. Ltd.
  • Serum Institute of India Pvt. Ltd.
  • Beijing Tiatan Biological Products Co. Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12364

“Inactivated Vaccines Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inactivated vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inactivated vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The inactivated vaccines market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Viral Vaccine; Bacterial Vaccine
  • 2) By Method Of Inactivation: Solvent Detergent; Radiation; pH Concentration; Heat Inactivation; Other Methods Of Inactivation
  • 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Sinopharm Group Co. Ltd.; Merck & Co. Inc.; Sanofi S.A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Inactivated vaccines, also known as killed vaccines, belong to a category of vaccines that contain viruses or bacteria that have been rendered nonfunctional or inactivated through methods like heat, chemicals, or radiation. These vaccines are specifically developed to elicit an immune response in the vaccinated individual without causing the disease itself.

The primary categories of inactivated vaccines include viral and bacterial vaccines. Viral vaccines are biological preparations containing weakened or inactivated virus components that serve to stimulate the immune system and provide immunity against the targeted viral infection. These viruses are rendered nonfunctional through processes such as solvent detergent treatment, radiation, pH adjustment, heat inactivation, and other methods. These vaccines are typically distributed through hospital pharmacies, retail pharmacies, and other relevant channels.

The inactivated vaccines market research report is one of a series of new reports from The Business Research Company that provides inactivated vaccines market statistics, including inactivated vaccines industry global market size, regional shares, competitors with an inactivated vaccines market share, detailed inactivated vaccines market segments, market trends and opportunities and any further data you may need to thrive in the inactivated vaccines industry. This inactivated vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The inactivated vaccines market size has grown steadily in recent years. It will grow from $5.95 billion in 2023 to $6.19 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to polio eradication efforts, influenza vaccination programs, emerging infectious diseases, regulatory approvals.

The inactivated vaccines market size is expected to see steady growth in the next few years. It will grow to $7.33 billion in 2028 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to pandemic preparedness, expanding vaccine coverage, biomanufacturing advancements, health equity initiatives. Major trends in the forecast period include mrna vaccine platforms, combination vaccines, thermostable vaccines, digital vaccine passports.

The rising prevalence of infectious diseases is anticipated to drive the expansion of the inactivated vaccine market in the future. Infectious diseases are illnesses caused by various pathogens, including bacteria, viruses, fungi, and parasites, which can be transmitted between individuals, leading to a broad spectrum of symptoms and health complications. Notably, tuberculosis is a representative infectious disease. Inactivated vaccines employ non-living pathogens to trigger an immune response, effectively safeguarding against diseases such as polio, hepatitis A, and influenza. As an illustration, the Global Tuberculosis Report published by the World Health Organization in October 2022 revealed that the global incidence of tuberculosis is projected to increase by 4.5% from 10.1 million cases to 10.6 million cases in 2021. The Southeast Asia region accounted for 45% of the total tuberculosis cases, while Africa reported 23% of the cases. Thus, the growing prevalence of infectious diseases is a key driver behind the expansion of the inactivated vaccine market.

The increasing immunization initiatives are poised to foster the growth of the inactivated vaccines market in the coming years. Immunization initiatives encompass organized campaigns and efforts designed to vaccinate individuals or communities against specific infectious diseases, ultimately shielding them from these health threats. The expansion of immunization initiatives constitutes a significant factor in the inactivated vaccines market. The proliferation of vaccination campaigns results in higher demand for inactivated vaccines, thereby stimulating market growth and encouraging investments in research and development. For instance, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicates that vaccines annually prevent 4-5 million lives from being lost globally due to infectious diseases like hepatitis, diphtheria, tetanus, pertussis (whooping cough), measles, and polio. Furthermore, in 2022, approximately 84% of infants worldwide received three doses of the polio vaccine. Similarly, an estimated 84% of infants in countries utilizing oral polio vaccine (OPV) received their initial inactivated polio vaccine (IPV) dose during the same year. Consequently, the growing immunization initiatives are a driving force behind the expansion of the inactivated vaccines market.

The presence of high fixed costs is a limiting factor for the growth of the inactivated vaccines market during the projected period. High fixed costs pose significant challenges to the inactivated vaccines industry, leading to reduced opportunities for innovation, restricted vaccine accessibility, elevated price points, diminished demand for vaccines, increased dependence on government subsidies, and decreased profitability for vaccine manufacturers. For example, in July 2022, data from the National Library of Medicine, a biomedical library, revealed that the establishment of production facilities for inactivated vaccines can exhibit substantial variability, with costs ranging from $50 million to $500 million per antigen. The complexity of the facility serves as the primary determinant for this cost variation. Consequently, the high fixed costs are acting as impediments to the expansion of the inactivated vaccines market.

Prominent companies engaged in the inactivated vaccines market are introducing cutting-edge and advanced inactivated vaccines to maintain their market positioning. Inactivated vaccines encompass vaccines containing non-live virus particles, bacteria, or other pathogens that have been cultured and subsequently rendered non-viable to eliminate their disease-causing capabilities. As an illustration, in January 2022, GSK PLC, a UK-based pharmaceutical and biotechnology enterprise, unveiled a novel inactivated vaccine known as Shingrix, designed for shingles protection. Shingrix is a non-live, recombinant subunit adjuvanted vaccine administered via intramuscular injection in two doses. Initially indicated for individuals aged 50 and older, its application has recently been expanded to encompass individuals aged 18 and older who face an elevated risk of developing shingles due to immunodeficiency or immunosuppression triggered by a known medical condition or medical treatment.

In April 2022, Albumedix Ltd., a UK-based biotechnology company, forged a collaboration with Valneva SE. This collaborative venture between Albumedix Ltd. and Valneva is expected to contribute to an augmentation in the production capacity of inactivated COVID-19 vaccines. The increased production capacity is intended to cater to the escalating demand for COVID-19 vaccines. Valneva SE is a French biotechnology enterprise with expertise in the discovery, manufacture, and distribution of inactivated vaccines designed to combat infectious diseases.

Major players in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

North America was the largest region in the inactivated vaccines market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inactivated vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The inactivated vaccines market consists of sales of whole-cell inactivated vaccines, subunit or protein subunit vaccines, conjugate vaccines and toxoid vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Inactivated Vaccines Market Characteristics

3. Inactivated Vaccines Market Trends And Strategies

4. Inactivated Vaccines Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Inactivated Vaccines Market Size and Growth

  • 5.1. Global Inactivated Vaccines Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Inactivated Vaccines Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Inactivated Vaccines Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Inactivated Vaccines Market Segmentation

  • 6.1. Global Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Viral Vaccine
  • Bacterial Vaccine
  • 6.2. Global Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Solvent Detergent
  • Radiation
  • pH Concentration
  • Heat Inactivation
  • Other Methods Of Inactivation
  • 6.3. Global Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Other Distribution Channels

7. Inactivated Vaccines Market Regional And Country Analysis

  • 7.1. Global Inactivated Vaccines Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Inactivated Vaccines Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Inactivated Vaccines Market

  • 8.1. Asia-Pacific Inactivated Vaccines Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Inactivated Vaccines Market

  • 9.1. China Inactivated Vaccines Market Overview
  • 9.2. China Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Inactivated Vaccines Market

  • 10.1. India Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Inactivated Vaccines Market

  • 11.1. Japan Inactivated Vaccines Market Overview
  • 11.2. Japan Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Inactivated Vaccines Market

  • 12.1. Australia Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Inactivated Vaccines Market

  • 13.1. Indonesia Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Inactivated Vaccines Market

  • 14.1. South Korea Inactivated Vaccines Market Overview
  • 14.2. South Korea Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Inactivated Vaccines Market

  • 15.1. Western Europe Inactivated Vaccines Market Overview
  • 15.2. Western Europe Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Inactivated Vaccines Market

  • 16.1. UK Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Inactivated Vaccines Market

  • 17.1. Germany Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Inactivated Vaccines Market

  • 18.1. France Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Inactivated Vaccines Market

  • 19.1. Italy Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Inactivated Vaccines Market

  • 20.1. Spain Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Inactivated Vaccines Market

  • 21.1. Eastern Europe Inactivated Vaccines Market Overview
  • 21.2. Eastern Europe Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Inactivated Vaccines Market

  • 22.1. Russia Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Inactivated Vaccines Market

  • 23.1. North America Inactivated Vaccines Market Overview
  • 23.2. North America Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Inactivated Vaccines Market

  • 24.1. USA Inactivated Vaccines Market Overview
  • 24.2. USA Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Inactivated Vaccines Market

  • 25.1. Canada Inactivated Vaccines Market Overview
  • 25.2. Canada Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Inactivated Vaccines Market

  • 26.1. South America Inactivated Vaccines Market Overview
  • 26.2. South America Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Inactivated Vaccines Market

  • 27.1. Brazil Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Inactivated Vaccines Market

  • 28.1. Middle East Inactivated Vaccines Market Overview
  • 28.2. Middle East Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Inactivated Vaccines Market

  • 29.1. Africa Inactivated Vaccines Market Overview
  • 29.2. Africa Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Inactivated Vaccines Market Competitive Landscape And Company Profiles

  • 30.1. Inactivated Vaccines Market Competitive Landscape
  • 30.2. Inactivated Vaccines Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Services Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Sinopharm Group Co. Ltd.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sanofi S.A.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Inactivated Vaccines Market Other Major And Innovative Companies

  • 31.1. GlaxoSmithKline plc
  • 31.2. Takeda Pharmaceutical Company Limited
  • 31.3. Astellas Pharma Inc.
  • 31.4. CSL Limited
  • 31.5. Daiichi Sankyo Company Limited
  • 31.6. Mitsubishi Tanabe Pharma Corporation
  • 31.7. Novavax Inc.
  • 31.8. Zydus Lifesciences Ltd.
  • 31.9. Sinovac Biotech Ltd.
  • 31.10. Biological E Limited
  • 31.11. Hualan Biological Engineering Inc.
  • 31.12. CanSino Biologics Inc.
  • 31.13. Shenzhen Kangtai Biological Products Co. Ltd.
  • 31.14. Serum Institute of India Pvt. Ltd.
  • 31.15. Beijing Tiatan Biological Products Co. Ltd.

32. Global Inactivated Vaccines Market Competitive Benchmarking

33. Global Inactivated Vaccines Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Inactivated Vaccines Market

35. Inactivated Vaccines Market Future Outlook and Potential Analysis

  • 35.1 Inactivated Vaccines Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Inactivated Vaccines Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Inactivated Vaccines Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer